Amphastar Pharma (AMPH) Tops Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2016
November 8, 2016 4:05 PM ESTReports Net Revenues of $64.2 Million for the Three Months Ended September 30, 2016
RANCHO CUCAMONGA, Calif., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (Amphastar or the Company) today reported results for the three months ended September 30, 2016.
Third Quarter Highlights
Net revenues of $64.2 million for the third quarterGAAP net income of $3.9 million, or $0.08 per diluted share for the third quarterAdjusted non-GAAP net income of $6.6 million, or $0.14 per diluted share for the third... More